Testing Strategies to Improving Warfarin Adherence

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00622102

Enrollment

101

Registered

2008-02-22

Start date

2007-12-31

Completion date

2009-04-30

Last updated

2009-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Deep Venous Thrombosis, Dilated Cardiomyopathies

Keywords

warfarin, adherence, Mechanical heart valves

Brief summary

We are performing a research study to learn more about the control of an individual's blood thinning (anticoagulation) on warfarin. Individuals from an anticoagulation clinic are being asked to participate in order to see if a lottery which provides the opportunity to win money in combination with the use of the Med-eMonitor might be useful in helping patients to achieve better control of their anticoagulation therapy. Half of the participants will be enrolled in the lottery arm and the other half will be a control group who will receive the Med-eMonitor only.

Interventions

BEHAVIORALLottery arm (Lottery and Med-eMonitor)

Lottery and Med-eMonitor

BEHAVIORALNon-Lottery (Med-eMonitor only)

Med-eMonitor only

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

21 Years to No maximum

Healthy volunteers

Inclusion criteria

* 21 years old age or older * On warfarin managed at the AC clinic * Target INR 2.0-3.0 or 2.5-3.5 * At maintenance phase of therapy (defined as stable INR with stable warfarin dosing over at least 2 consecutive visits)

Exclusion criteria

* Do not have access to telephone line * Unwillingness to participate or to sign a consent form(refusal) * Inability to participate because of advances dementia, advanced Alzheimer's disease or other impairment affecting ability to provide informed consent and/or quality data or utilize the Med-eMonitor * Participation in a current study that does not permit participation in another study * End stage or terminal illness with anticipated life expectancy of 6 months or less * INR over the upper limit for the individual's range at the time of enrollment (e.g.,\>3.0 or \>3.5, depending on the target range) * Diagnosed with antiphospholipid antibody syndrome or abnormal INR prior to starting warfarin

Design outcomes

Primary

Measure	Time frame
anticoagulation control	six months

Secondary

Measure	Time frame
adherence	six months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026